Related Experiment Video
Updated: Aug 8, 2025

Echocardiographic Assessment Using Subxiphoid-Only Examination for Hypotensive Patients
Published on: April 18, 2025
Protocolised reduction of non-resuscitation fluids versus usual care in patients with septic shock (REDUSE): a
Anja Lindén1, Jane Fisher2, Gisela Lilja3
1Anesthesiology and Intensive Care, Department of Clinical Sciences Lund, Helsingborg Hospital, Lund University, Helsingborg, Sweden anja.linden@gmail.com.
Introduction:
Administration of large volumes of fluids is associated with poor outcome in septic shock. Recent data suggest that non-resuscitation fluids are the major source of fluids in the intensive care unit (ICU) patients suffering from septic shock. The present trial is designed to test the hypothesis that a protocol targeting this source of fluids can reduce fluid administration compared with usual care.
Methods And Analysis:
The design will be a multicentre, randomised, feasibility trial. Adult patients admitted to ICUs with septic shock will be randomised within 12 hours of admission to receive non-resuscitation fluids either according to a restrictive protocol or to receive usual care. The healthcare providers involved in the care of participants will not be blinded. The participants, outcome assessors at the 6-month follow-up and statisticians will be blinded. Primary outcome will be litres of fluids administered within 3 days of randomisation. Secondary outcomes will be proportion of randomised participants with outcome data on all-cause mortality; days alive and free of mechanical ventilation within 90 days of inclusion; any acute kidney injury and ischaemic events in the ICU (cerebral, cardiac, intestinal or limb ischaemia); proportion of surviving randomised patients who were assessed by European Quality of Life 5-Dimensions 5-Level questionnaire and Montreal Cognitive Assessment; proportion of all eligible patients who were randomised and proportion of participants experiencing at least one protocol violation.
Ethics And Dissemination:
Ethics approval has been obtained in Sweden. Results of the primary and secondary outcomes will be submitted for publication in a peer-reviewed journal.
Trial Registration Number:
NCT05249088.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Heart Failure VI: Adjunct Therapies
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Heart Failure V: Medical Management

